Use of progestogens in pregnant and infertile patients

Archives of Gynecology and Obstetrics

Volumn 286, Issue 2, 2012, Pages 495-503

  Özlü, Tülay ^a   Güngör, Ayoenur Çakir ^b   Dönmez, Melahat Emine ^a   Duran, Bülent ^a  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

^b ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

Author keywords

Abortion; Luteal phase; Preterm; Progesterone; Progestogen; Short cervix

Indexed keywords

ANTIBIOTIC AGENT; CHORIONIC GONADOTROPIN; CORTICOSTEROID; DYDROGESTERONE; ESTROGEN; GESTAGEN; GONADORELIN AGONIST; HYDROXYPROGESTERONE CAPROATE; PLACEBO; PROGESTERONE; UTERUS SPASMOLYTIC AGENT;

ARTICLE; CERVICAL LENGTH MEASUREMENT; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FATIGUE; FERTILIZATION IN VITRO; FETUS WASTAGE; FIRST PASS EFFECT; GEL; HIGH RISK POPULATION; HUMAN; IMMINENT ABORTION; INFERTILITY; INJECTION SITE REACTION; LUTEAL PHASE; MULTIPLE PREGNANCY; PAIN; PREGNANCY; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PREMATURE OVARIAN FAILURE; RECURRENT ABORTION; SINGLE DRUG DOSE; SKIN IRRITATION; SOMNOLENCE; SPONTANEOUS ABORTION; SYSTEMIC DISEASE; TWIN PREGNANCY; UTERINE CERVIX INCOMPETENCE; VAGINA DISEASE; VAGINA IRRITATION;

ABORTION, HABITUAL; CERVICAL LENGTH MEASUREMENT; EMBRYO IMPLANTATION; FEMALE; FETAL MEMBRANES, PREMATURE RUPTURE; HUMANS; INFERTILITY, FEMALE; LUTEAL PHASE; PREGNANCY; PREGNANCY, MULTIPLE; PREMATURE BIRTH; PRIMARY OVARIAN INSUFFICIENCY; PROGESTINS; RISK; TOCOLYTIC AGENTS; ULTRASONOGRAPHY, PRENATAL;

EID: 84864428332     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-012-2340-4     Document Type: Article

References (65)

1. Cunningham FG (ed) (2010) Williams obstetrics, 23rd edn. McGraw-Hill, New York
2. Carey WD (ed) (2009) Cleveland clinic current clinical medicine, 2nd edn. Saunders, Philadelphia
3. Gabbe SG (ed) (2007) Gabbe: obstetrics: normal and problem pregnancies, 5th edn. Churchill Livingstone, Philadelphia
4. Meis PJ, Connors N (2004) Progesterone treatment to prevent preterm birth. Clin Obstet Gynecol 47:784-795
5. Stites DP, Bugbee S, Siiteri PK (1983) Differential action of progesterone and cortisol on lymphocyte and monocyte interaction during lymphocyte activation - relevance to immunosuppression in pregnancy. J Reprod Immunol 5:215-228
6. Palagiano A, Bulletti C, Pace MC, De Ziegler D, Cicinelli E, Izzo A (2004) Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann NY Acad Sci 1034:200-210
7. Dodd JM, Flenady V, Cincotta R, Crowther CA (2006) Prenatal administration of progesterone for preventing preterm birth. Cochrane Database Syst Rev 25(1):CD004947
8. Nielsen S, Hahlin M, Platz-Christensen J (1999) Randomised trial comparing expectant with medical management for first trimester miscarriage. Br J Obstet Gynaecol 106:804-807
9. Tang OS, Chan CC, Ng EH, Lee SW, Ho PC (2003) A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than × weeks gestation. Hum Reprod 18(11):2315-2318
10. Majhi P, Bagga R, Kalra J, Sharma M (2009) Intravaginal use of natural micronised progesterone to prevent pre-term birth: a randomised trial in India. J Obstet Gynaecol 29(6):493
11. US Department of Health and Human Services (2011) Food and Drug Administration Statement on Makena.(press release), 30 Mar 2011 US Department of Health and Human Services, Silver Spring
12. Omar MH, Mashita MK, Lim PS, Jamil MA (2005) Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol 97(5):421-425 Epub 2005 Nov 15
13. Gruber CJ, Huber JC (2005) The role of dydrogesterone in recurrent (habitual) abortion. J Steroid Biochem Mol Biol 97(5): 426-430 Epub 2005 Sep 26
14. Mattison DR, Damus K, Fiore E, Petrini J, Alter C (2001) Preterm delivery: a public health perspective. Paediatr Perinat Epidemiol 15(Suppl 2):7-16
15. Iams JD, Romero R, Culhane JF, Goldenberg RL (2008) Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet 371(9607):164
16. Tita AT, Rouse DJ (2009 Mar) Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol 200(3):219-224
17. Newman RB, Campbell BA, Stramm SL (1990) Objective tocodynamometry identifies labor onset earlier than subjective maternal perception. Obstet Gynecol 76:1089-1092
18. Yemini M, Borestein R, Dreazen E, Apelman Z, Molginer BM, Kessler I et al (1985) Prevention of premature labor by 17 α-hydroxyprogesterone caproate. Am J Obstet Gynecol 151:574-577
19. Dodd JM, Flenady VJ, Cincotta R, Crowther CA (2008) Progesterone for the prevention of preterm birth: a systematic review. Obstet Gynecol 112(1):127
20. Waters TP, Schultz BA, Mercer BM, Catalano PM (2009) Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy. Obstet Gynecol 114(1):45
21. Rebarber A, Istwan NB, Russo-Stieglitz K, Cleary-Goldman J, Rhea DJ, Stanziano GJ et al (2007) Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 30(9):2277-2280 Epub 2007 Jun 11
22. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network., 4 (2009) The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. Am J Obstet Gynecol 201(4):392.e1
23. Rebarber A, Ferrara LA, Hanley ML, Istwan NB, Rhea DJ, Stanziano GJ et al (2007) Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 196(3):224.e1
24. Briery CM, Veillon EW, Klauser CK, Martin RW, Magann EF, Chauhan SP, Morrison JC (2011) Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. Am J Obstet Gynecol 204(1):54.e1-5
25. Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S et al (2009) Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebocontrolled study and meta-analysis. Lancet 373(9680):2034
26. Obstetrix Collaborative Research Network (2011) 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 204(3):221.e1
27. PREDICT Group (2011) Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 38(3):272
28. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network (2010) Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17- αhydroxyprogesterone caproate. J Matern Fetal Neonatal Med 23(12):1360
29. PREDICT Group (2011) Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis. Ultrasound Obstet Gynecol 38(3):281
30. National Institute of Child Health and Human Development (NICHD), Maternal-Fetal Medicine Units Network (MFMU) (2009) Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol 113(2 Pt 1):285
31. Obstetrix Collaborative Research Network (2010) Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 203(3):248.e1
32. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH (2007) Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 357:462-469
33. Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M (2000) Maternal age and fetal loss: population based register linkage study. Br Med J 320:1708-1712
34. Wilcox AJ, Weinberg CR, O'Connor JF (1988) Incidence of early loss of pregnancy. N Engl J Med 319:189-194
35. Abramson J, Stagnaro-Green A (2001) Thyroid antibodies and fetal loss: an evolving story. Thyroid 11(1):57
36. Li TC, Iqbal T, Anstie B, Gillham J, Amer S, Wood K et al (2002) An analysis of the pattern of pregnancy loss in women with recurrent miscarriage. Fertil Steril 78(5):1100-1106
37. Haas DM, Ramsey PS (2008) Progestogen for preventing miscarriage. Cochrane Database Syst Rev 16(2):CD003511
38. Coomarasamy A, Truchanowicz EG, Rai R (2011) Does first trimester progesterone prophylaxis increase the live birth rate in women with unexplained recurrent miscarriages? BMJ 342:d1914
39. Choi BC, Polgar K, Xiao L, Hill JA (2000) Progesterone inhibits in vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. Hum Reprod 15(Suppl 1): 46
40. World Health Organization (1992) International statistical classification of diseases and related health problems, vol 1, 10th edn. World Health Organization, Geneva
41. Wahabi HA, Abed Althagafi NF, Elawad M, Al Zeidan RA (2011) Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 16(3):005943
42. Gerhard I, Gwinner B, Eggert-Kruse W, Runnebaum B (1987) Doubleblind controlled trial of progesterone substitution in threatened abortion. Biol Res Pregnancy Perinatol 8:26-34
43. Silver RI, Rodriguez R, Chang TS, Gearhart JP (1999) In vitro fertilization is associated with an increased risk of hypospadias. J Urol 161(6):1954-1957
44. Dudas I, Gidai J, Czeizel AE (2006) Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. Congenit Anom 46(4):194-198
45. Katz Z, Lancet M, Skornik J, Chemke J, Mogilner BM, Klinberg M (1985) Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol 65(6):775-780
46. El-Zibdeh MY, Yousef LT (2009) Dydrogesterone support in threatened miscarriage. Maturitas 65(Suppl 1):S43-S46 Epub 2009 Dec 14.
47. Pandian RU (2009) Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 65(Suppl 1):S47-S50 Epub 2009 Dec 14
48. Regan L, Rai R (2000) Epidemiology and the medical causes of miscarriage. Baillieres Best Pract Res Clin Obstet Gynaecol 14(5):839
49. Balasch J, Fábregues F, Creus M, Vanrell JA (1992) The usefulness of endometrial biopsy for luteal phase evaluation in infertility. Hum Reprod 7(7):973
50. Davis OK, Berkeley AS, Naus GJ, Cholst IN, Freedman KS (1989) The incidence of luteal phase defect in normal, fertile women, determined by serial endometrial biopsies. Fertil Steril 51(4):582
51. Ogasawara M, Kajiura S, Katano K, Aoyama T, Aoki K (1997) Are serum progesterone levels predictive of recurrent miscarriage in future pregnancies? Fertil Steril 68(5):806-809
52. Ubaldi F, Bourgain C, Tournaye H, Smitz J, Van Steirteghem A, Devroey P (1997) Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase. Fertil Steril 67:521-526
53. Macklon NS, Fauser BC (2000) Impact of ovarian hyperstimulation on the luteal phase. J Reprod Fertil 55(Suppl):101-108
54. Burney RO, Schust DJ, Yao MWM (2006) Infertility. In: Berek JS (ed) Berek & Novak's Gynecology. Lippincott Williams & Wilkins, Philadelphia, pp 1185-1275
55. Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P (2007) An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update 13(6):581-590 Epub 2007 Jul 11
56. Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S (2005) Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol 97:416-420
57. Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C (2006) Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonistand antagonist-treated ovarian stimulation cycles. Hum Reprod 21(10):2572-2579 Epub 2006 Aug 22
58. van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M (2011) Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 5(10):009154
59. Silverberg KM, Vaughn TC, Hansard LJ, Burger NZ, Minter T (2012) Vaginal (Crinone 8 %) gel vs. intramuscular progesterone in oil for luteal phase support in in vitro fertilization: a large prospective trial. Fertil Steril 97(2):344-348 Epub 2011 Dec 19
60. Kyrou D, Fatemi HM, Zepiridis L, Riva A, Papanikolaou EG, Tarlatzis BC et al (2011) Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Hum Reprod 26(5):1020
61. Aboulghar MA, Amin YM, Al-Inany HG, Aboulghar MM, Mourad LM, Serour GI, Mansour RT (2008) Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. Hum Reprod 23(4):857
62. Devroey P, Pados G (1998) Preparation of endometrium for egg donation. Hum Reprod Update. 4(6):856-861
63. Pritts EA, Atwood AK (2002) Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 17(9):2287
64. Bourgain C, Devroey P, Van Waesberghe L, Smitz J, Van Steirteghem AC (1990) Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Reprod 5(5):537
65. Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P (2000) Direct transport of progesterone from vagina to uterus. Obstet Gynecol 95(3):403